Clinical and genomic characteristics of hepatocellular carcinoma-cholangiocarcinoma: Insights from real-world data.

• DOI: 10.1200/jco.2025.43.4_suppl.556
• Publication Date: 2025-01-27T14:33:47Z
• Authors: Oluseyi Abidoye; Isabela Chang; Celine Hoyek; Angelo Pirozzi; Naohiro Okano; Binbin Zheng-Lin; Heidi E. Kosiorek; Cody Eslinger; Mohamad B. Sonbol; Daniel H. Ahn; Christina Wu; Takayuki Yoshino; Masafumi Ikeda; Chigusa Morizane; Hideaki Bando; Yoshiaki Nakamura; Takao Fujisawa; Taro Shibuki; Mitesh J. Borad; Tanios S. Bekaii-...
• Keywords: Real world data

556 Background: Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) is a rare and complex liver cancer with features of both carcinoma (HCC) cholangiocarcinoma (CCA), making its management challenging. This study aims to analyze the clinical characteristics, genomic profiles, treatment outcomes cHCC-CCA patients in real-world setting. Methods: We conducted retrospective analysis across three first-line groups: chemotherapy alone(Gemcitabine/Cisplatin, FOLFOX), HCC-directed therapies (atezolizumab/bevacizumab, lenvatinib, nivolumab, durvalumab, sorafenib), chemoimmunotherapy (Gemcitabine/Cisplatin combined immunotherapy). international study, involving Mayo Clinic National Cancer Center East (Japan), assessed overall survival (OS) using Kaplan-Meier Cox regression models. Results: A total 68 were included, mean age 66 years; 74% male 66% White Non-Hispanics. Cirrhosis was present at diagnosis, Hepatitis B C common etiologies 57%. Prior primary resection regional (Transarterial chemoembolization (TACE), Transarterial radioembolization (TARE)) recorded 39% 50% patients, respectively. Advanced/metastatic disease 52% cohort. The distribution treatments as follows: 47% received alone, therapy, 14% chemoimmunotherapy. Genomic alterations detected 44% TP53 (28%), ARID1A (25%), TERT (22%) being most frequent. therapy group demonstrated best response rate (52%) had median OS 15.8 months (mo), compared 11.8 mo for 4.7 (p=0.8). Patients who longer those did not (10.2 mo) (p=0.4). Conclusions: showed trend towards better other treatments, though statistically significant. considerable proportion alterations, which may have influenced outcomes. Ongoing research larger cohorts underway further elucidate impact variations on efficacy refine therapeutic strategies this challenging malignancy. Baseline characteristics (cHCC-CCA). Total(N=68) Mean years (SD) 66(6.4) Gender, n (%) Male 50 (74%) Ethnicity, White, Non-Hispanic 45 (66%) Etiology Liver disease, Viral (Hepatitis C) 39 (57%) History Primary resection, 27 (39%) Regional treatment, 34 (50%) Afp, < 200 23 (64%) ca19_9, (82%)